Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, et al. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv41–50.
2. Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D’Sa S, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020;7:e827–37.
3. Pratt G, El-Sharkawi D, Kothari J, D’Sa S, Auer R, McCarthy H, et al. Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol. 2022;197:171–87.
4. Del Giudice I, Matutes E, Osuji N, Parry-Jones N, Swansbury J, Catovsky D. Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia. Haematologica 2005;90:268–70.
5. Varghese AM, Rawstron AC, Ashcroft AJ, Moreton P, Owen RG. Assessment of bone marrow response in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:53–5.